Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

calcium channel agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (4) Calmodulin (2) Piezo Channel (1) Potassium Channel (2) Adrenergic Receptor (1) Akt (1) Apoptosis (3) ERK (1) mAChR (1) mGluR (2) Phosphodiesterase (PDE) (2) PPAR (1)
By Research Areas:	Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Targets Recommended: Calcium Channel CRAC Channel CaSR Calmodulin Chloride Channel HCN Channel TRP Channel Sodium Channel Potassium Channel Piezo Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1077A

CALP1 TFA 1 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 TFA is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of **calcium channel** opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates CaM-dependent phosphodiesterase activity .

HY-18723

Yoda 1 Maximum Cited Publications 32 Publications Verification	Piezo Channel Akt ERK Potassium Channel	Cardiovascular Disease
Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca ²⁺ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation .

HY-12498

GV-58	Calcium Channel	Neurological Disease
GV-58 is a novel N- and P/Q-type calcium (Ca ²⁺) channel agonist with EC₅₀s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca ²⁺ entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research .

HY-120535

RS 30026	Calcium Channel	Neurological Disease
RS 30026 is a potent **calcium channel** agonist with a pEC₅₀ value of 7.45 .

HY-P1077

CALP1	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of **calcium channel** opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity .

HY-117223

GEA 857	Potassium Channel	Neurological Disease
GEA 857 is a structural analog of the Serotonin (HY-B1473A) uptake blocker Alaproclate (HY-164011). GEA 857 enhances responses induced by muscarinic receptor agonists by inhibiting certain calcium-dependent potassium channels on membranes, a blockade that can enhance or prolong the muscarinic cholinergic effects. GEA 857 can be used in research on neurodegenerative diseases .

HY-151198

CHF-6366	mAChR Adrenergic Receptor Calcium Channel	Inflammation/Immunology Endocrinology
CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pK_i values of 10.4 and 11.4, respectively. CHF-6366 is also a weak **calcium channel inhibitor (IC₅₀**~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .

HY-121746

GW7845	PPAR Calcium Channel Apoptosis	Cardiovascular Disease Metabolic Disease
GW7845 is an orally active non-thiazolidinedione, tyrosine-derived PPARγ agonist. GW7845 is effective at inhibiting *voltage-dependent calcium* channels (VDCC) and relaxing pressurized arteries with IC₅₀ of 3 μM by using Ba ²⁺ as the charge carrier through VDCC. GW7845-induced apoptosis** is mitochondria- and apoptosome-dependent. GW7845 induces rapid mitochondrial membrane depolarization and release of cytochrome c in primary pro-B cells and BU-11 cells .

Cat. No.	Product Name

HY-L070

Neuroprotective Compound Library	1,140 compounds
Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases. MCE offers a unique collection of 1,140 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Neuroprotective Compound Library

1,140 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1,140 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1077A

CALP1 TFA 1 Publications Verification	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 TFA is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of **calcium channel** opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates CaM-dependent phosphodiesterase activity .

HY-P1077

CALP1	mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin	Inflammation/Immunology
CALP1 is a calmodulin (CaM) agonist (K_d of 88 µM) with binding to the CaM EF-hand/Ca ²⁺-binding site. CALP1 blocks calcium influx and apoptosis (IC₅₀ of 44.78 µM) through inhibition of **calcium channel** opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.